The Novogene Precision Medicine 2.0 (NovoPM™ 2.0) comprehensive genomic profiling test for solid tumors is a hyphenate sequencing (NGS)-based assay that analyzes 484 genes for clinically important alterations at the DNA level. These genes are known to be relevant for the diagnosis and/or treatment of various solid tumors according to National Comprehensive Cancer Network (NCCN) Guidelines and the medical literature. All tests are performed in our CAP-accredited lab and analyzed by our in-house bioinformatics specialists. Report generated provides tailored treatment recommendations for your patients.
NovoPM™ 2.0 is developed based on NovoPM™ 1.0 with updated gene list and enhanced analytical performance.
NovoPM™ 2.0 interrogates the complete coding regions of 468 genes and the introns of 43 genes. It can detect all four types of genomic abnormalities(SNV, InDel, CNV and Fusion) and also generate results (TMB, bTMB and MSI）that can help guide cancer immunotherapies.
Comprehensive analytical validation has been completed and the test includes rigorous quality control measures.
As a high-tech life science company in Beijing, Novogene can utilize a government-authorized "green channel" for ultra-fast importation of clinical samples through the Beijing Customs, when necessary.
With one of the world's largest sequencing capacity and superior process efficiency, Novogene offers highly competitive prices for all services.
NovoPM™ 2.0 interrogates the complete coding regions of 468 genes and the introns of 43 genes for all four types of genomic abnormalities: SNV, InDel, CNV and fusion. A comparison of the gene lists between NovoPM™ 2.0 and the FDA-approved FoundationOne CDx is shown in Figure 1. The mutation status of some of these genes can guide the potential application of multiple FDA-approved targeted and/or immunotherapies as shown in Table below. The other genes are also analyzed for their relevance to the diagnosis and/or treatment of various solid tumors according to the medical literature. The clinical interpretation of detected mutations in those genes is done according to Novogene’s comprehensive in-house oncology knowledgebase constructed based on public resources including GeneCards, CKB, OncoKB, ClinVar PMC, Drugs@FDA, Drug Information Portal (NIH), Selleck, PharmGKB, DGIdb, DRUGBANK, Drugs.com, ClinicalTrials.gov, ICTRP, ChiCTR, KEGG and Cell Signaling. In addition, our oncology knowledgebase incorporates ~1,000 germline BRCA1/2 variants previously reported to be unique in Chinese breast cancer and ovarian cancer patients1.
Figure 1. NovoPMTM 2.0 vs. FoundationOne CDx
Table 1. Gene targets in NovoPMTM 2.0 that are associated with FDA-approved or NCCN-recommended therapies
The field is required.
I agree that Novogene Corporation may use this information to contact me to assist with my request. I understand that all personal information I have submitted will be kept confidential in accordance with Novogene's privacy policy.